BioSpace News Archive

With cell and gene expertise in high demand, industry innovator will help expand the leading cloud-based software “platform of record”...

ALN-AAT02 is the First Investigational RNAi Therapeutic to Utilize Alnylam’s Enhanced Stabilization Chemistry Plus (ESC+) GalNAc-Conjugate Technology

Research agreement for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli.

Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s commitment to furthering movement disorders research

Cellular Biomedicine Group Inc. today announced it has entered into a Patent License Agreement (the “License Agreement”) with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services.

Babies from FIREFISH Part 1 study showed increased survival & gains in developmental milestones

Radius Health, Inc. today announced the latest 2019 Medicare Part D coverage for TYMLOS which increased to approximately 26.2 million lives or 64% of those enrolled in Medicare Part D plans in the U.S.

Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2018 taking place October 3 - 7, 2018 in San Francisco, California.

$12 million underwritten public offering closed October 2 $4.9 million registered direct offering closed September 26

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today the appointment of Robert Foster, Pharm.D., Ph.D. as its acting Chief Executive Officer, effectively immediately.